PROVAS – Treatment of coronary heart disease and other clinical conditions relating to a deficit in endothelial progenitor cells

Endothelial progenitor cells are bone-marrow-derived cells that circulate in the blood and have the ability to differentiate into endothelial cells. The amount of

endothelial progenitor cells is affected by numerous factors. A decreased number and function of endothelial progenitor cells was observed in patients suffering from different disorders. The reason for decreased levels of endothelial progenitor cells and the clinical effect still remains unclear. Experimental therapy of a deficit of endothelial progenitor cells currently is limited to infusion of endothelial progenitor cells or stem cells. Such infusions are complex and the therapeutic success at present is limited. The adenosine level especially in the blood plasma can affect the level of endothelial progenitor cells. Adenosine level affecting-compounds can increase the viability of endothelial progenitor cells. It is of particular therapeutic value that adenosine level affecting-compounds can induce an increase of the level of endothelial progenitor cells and at the same time can reduce the amount of apoptotic endothelial progenitor cells. The present invention discloses the use of adenosine level affecting-compounds e.g. dipyridamole, adenosine and its analogues (alone or in combination with other groups of compounds) for the t reatment or diagnosis of clinical conditions resulting from a deficit of endothelial progenitor cells, especially coronary heart disease.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert